A powerful new testing system for medical cannabis in Canada
Updated: Sep 6, 2020
Bruker and Purity-IQ have joined forces to create a powerful new testing system for medical cannabis in Canada. The Purity-IQ Cannabis Fingerprint combines Bruker’s expertise in nuclear magnetic resonance (NMR) based screening technology with Purity-IQ’s genomics capabilities to offer traceability and identity testing throughout the cannabis supply chain.
There are currently no standardized regulations between states or countries for quality control in cannabis, making it difficult for consumers to make informed decisions about the product they are purchasing. Bringing two powerful technologies together gives the supply chain the opportunity to move the cannabis industry to a consistent and compliant platform.
Cannabis producers and manufacturers need to ensure product quality and consistency of strain and dosage, especially as regulatory standards continue to shift, and retailers such as pharmacies and dispensaries must protect their brand and provide consumers with a product they can trust.
Identifying the genomic profile and chemical compounds in a cannabis cultivar is the key to providing consistent quality and dosing assurance. The Purity-IQ Global Cannabis Registry is the only database derived from the genomic and metabolomic identification of cannabis and hemp products, and will serve to satisfy the industry need for tracking and tracing within the supply chain. Genomics is used to determine cannabis identity and heredity and NMR determines the purity and consistency of the product at a molecular level, providing traceability, authenticity and identity throughout the supply chain from plant to finished product. This is achieved through creating a unique chemical “fingerprint,” using the Purity-IQ Cannabis Fingerprint to create new Cannabis Authenticity and Purity Standard (CAPS).